Physician profile
Gregory S Smith
NPI 1992807242
$30,530.91
in general payments reported to CMS, 2019-2025
43 companies · $644 in 2025
The $644 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,830 · 2020: $953 · 2021: $717 · 2022: $1,166 · 2023: $24K · 2024: $840 · 2025: $644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $24K · Food and Beverage: $2,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $23,605.62 |
| Food and Beverage | $2,258.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $23,618.87 | 2022-2023 | Ruhof Scope Valet Guardian |
| Abbvie INC. | $2,059.69 | 2019-2025 | Mavyret, Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $753.04 | 2019-2023 | Xifaxan |
| Boston Scientific Corporation | $697.18 | 2019-2024 | Exalt Model D |
| Pfizer INC. | $365.34 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $355.28 | 2022-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $281.29 | 2019-2025 | Entyvio |
| Genzyme Corporation | $261.52 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $185.37 | 2019-2024 | Ocaliva |
| Ucb, INC. | $177.92 | 2019-2020 | |
| Janssen Biotech, INC. | $176.32 | 2021-2024 | Stelara |
| Gilead Sciences, INC. | $169.32 | 2019-2022 | |
| Qol Medical, LLC | $167.93 | 2023-2024 | Sucraid, Sucraid |
| Redhill Biopharma INC. | $115.07 | 2020-2023 | |
| Celgene Corporation | $109.97 | 2021-2023 | Zeposia |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.